Marta Moreno, Aissata Barry, Markus Gmeiner, Jean Baptist Yaro, Samuel S Sermé, Isabel Byrne, Jordache Ramjith, Alphonse Ouedraogo, Issiaka Soulama, Lynn Grignard, Seyi Soremekun, Simon Koele, Rob Ter Heine, Amidou Z Ouedraogo, Jean Sawadogo, Edith Sanogo, Issa N Ouedraogo, Denise Hien, Sodiomon Bienvenu Sirima, John Bradley, Teun Bousema, Chris Drakeley, Alfred B Tiono
INTRODUCTION: Seasonal malaria chemoprevention (SMC) involves repeated administrations of sulfadoxine-pyrimethamine plus amodiaquine to children below the age of 5 years during the peak transmission season in areas of seasonal malaria transmission. While highly impactful in reducing Plasmodium falciparum malaria burden in controlled research settings, the impact of SMC on infection prevalence is moderate in real-life settings. It remains unclear what drives this efficacy decay. Recently, the WHO widened the scope for SMC to target all vulnerable populations...
March 12, 2024: BMJ Open